Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-05, Stock:ABBV, The news for the past five days is as follows:
2018-09-28: NEWS1: AbbVie (ABBV) Stock Moves 0.47%: What You Should Know.NEWS2: AbbVie (ABBV) Stock Moves 0.47%: What You Should Know.NEWS3: RM LAW Announces Class Action Lawsuit Against AbbVie Inc..NEWS4: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors.NEWS5: AbbVie (ABBV) Stock Moves 0.47%: What You Should Know.NEWS6: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.NEWS7: SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS8: CLASS ACTION UPDATE for MCHP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS9: Healthcare: 2 Hot Biotech Stocks on Our Radar.NEWS10: Healthcare: 2 Hot Biotech Stocks on Our Radar.NEWS11: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS12: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS13: Healthcare: 2 Hot Biotech Stocks on Our Radar.NEWS14: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018.NEWS15: ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action.
2018-10-01: NEWS1: ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS2: Health Care Sector Update for 10/01/2018: SYK,TLRY,TARO,MNTA,ABBV,REGN,MYL.NEWS3: Health Care Sector Update for 10/01/2018: SYK,TLRY,TARO,MNTA,ABBV,REGN,MYL.NEWS4: 5 Reasons to Buy Gilead Stock Today.NEWS5: 5 Reasons to Buy Gilead Stock Today.NEWS6: AbbVie Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV.NEWS7: 5 Reasons to Buy Gilead Stock Today.NEWS8: Top Analyst Reports for ExxonMobil, Disney & AbbVie.NEWS9: Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL.NEWS10: Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL.NEWS11: AbbVie’s Dividend Has Risen 140% since 2013.NEWS12: Research Report Identifies AbbVie, NMI, Dollar Tree, Scotts Miracle-Gro, Halliburton, and Microchip Technology with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement.
2018-10-02: NEWS1: 5 Health Care Stocks Gurus Are Buying.NEWS2: Here's Why Antares Pharma Jumped Higher Today.NEWS3: Here's Why Antares Pharma Jumped Higher Today.NEWS4: Here&apos;s Why Antares Pharma Jumped Higher Today.NEWS5: Examining the Performances of Eli Lilly’s Oncology Products.NEWS6: The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental.NEWS7: The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental.NEWS8: How Eli Lilly’s Cardiovascular Products Have Been Faring.NEWS9: The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental.NEWS10: IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.
2018-10-03: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors.NEWS3: Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors.NEWS4: Cramer's lightning round: The sweet spot for buying shares of Clorox.NEWS5: Noteworthy Wednesday Option Activity: FIT, ROST, ABBV.NEWS6: Noteworthy Wednesday Option Activity: FIT, ROST, ABBV.NEWS7: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS8: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS9: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS10: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS11: Merck & Other Pharma Players Await FDA Decisions in October.NEWS12: Merck & Other Pharma Players Await FDA Decisions in October.NEWS13: Here&apos;s Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS14: Mylan’s Humira Biosimilar Opportunity in Europe.NEWS15: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS16: The hidden dangers of testosterone replacement therapy you should know about.NEWS17: Nobel Recognizes Science Leading to AbbVie&apos;s Top-Selling Drug.
2018-10-04: NEWS1: Gauging the Impact of AbbVie’s Share Repurchases.NEWS2: What AbbVie’s Valuation Trend Indicates.NEWS3: How Is AbbVie Expected to Fare Going Forward?.NEWS4: IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS5: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018.NEWS6: Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US.NEWS7: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.

Answer: Rise